Mumbai (Maharashtra) [India], Aug 21 (ANI): India Ratings and Research (Ind-Ra) has said the decline in US sales of Indian companies was attributed to a high single-digit price erosion in US generic market coupled with a continued weak demand for the acute portfolio of products during 1Q FY2
New Delhi [India], Oct 5 (ANI): The growth and profitability of Indian pharmaceutical companies in current financial year will be constrained by regulatory interventions like price controls in domestic market and compulsory genericisation in overseas market, according to ICRA Ratings.